ASCO22: Breast cancer research by Sara Tolaney, MD
Breast Cancer phase 3 study results TROPiCS-02 at #ASCO22 : Dana-Farber's Sara Tolaney, MD, senior author, says research shows new antibody-drug conjugate produced improved progression-free survival rates compared to chemotherapy in HR+/HER2-neg advanced breast cancer.
traffic. So too, was a randomized phase three trial for patients that had pre treated hormone receptor positive, her two negative metastatic breast cancer that had already progressed on endocrine therapy and a c. D. K 46 inhibitor. And in patients who had received at least two lines of chemotherapy and no more than four the metastatic setting. And these patients were randomized to receive SAS ETTA's um at Vatican, a novel antibody drug conjugate or to receive standard chemotherapy of physicians choice. The study demonstrated that Societa Samad was associated with a significant improvement in progression free survival, going from four months in the control arm to 5.5 months with the Sas Atas a mob. This is consistent with a 34% reduction in risk of disease progression or death. So a hazard ratio of .66. And so I think these data really suggests that society is a map should be considered a potential therapeutic option for patients with pre treated hormone receptor positive metastatic breast cancer.
